Raffaele De Caterina

Prof. Raffaele De Caterina

University of Pisa, Pisa, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2004 in Cardiovascular Research
Verified
Journal Article
Closed access
Giuseppina BastaGiuseppina Basta
Giuseppina Basta
ASAnn Marie Schmidt
Ann Marie Schmidt
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
The formation of advanced glycation end products (AGEs) is an important biochemical abnormality that accompanies diabetes mellitus and, likely, inflammation in general. Here we summarize and discuss recent studies indicating that the effects of AGEs on vessel wall homeostasis may account for the rapidly progressive atherosclerosis associated with diabetes mellitus. Driven by hyperglycemia and oxidant stress, AGEs form to a greatly accelerated degree in diabetes. Within the vessel wall, collagen-linked AGEs may "trap" plasma proteins, quench nitric oxide (NO) activity and interact with specific receptors to modulate a large number of cellular properties. On plasma low density lipoproteins (LDL), AGEs initiate oxidative reactions that promote the formation of oxidized LDL. Interaction of AGEs with endothelial cells as well as with other cells accumulating within the atherosclerotic plaque, such as mononuclear phagocytes and smooth muscle cells (SMCs), provides a mechanism to augment vascular dysfunction. Specifically, the interaction of AGEs with vessel wall components increases vascular permeability, the expression of procoagulant activity and the generation of reactive oxygen species (ROS), resulting in increased endothelial expression of endothelial leukocyte adhesion molecules. AGEs potently modulate initiating steps in atherogenesis involving blood-vessel wall interactions, triggering an inflammatory-proliferative process and, furthermore, critically contribute to propagation of inflammation and vascular perturbation in established disease. Thus, a better understanding of the biochemical mechanisms by which AGEs contribute to such processes in the vessel wall could be relevant to devise preventive and therapeutic strategies for diabetic atherosclerosis.

23 June 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
CVD is the leading cause of death worldwide; preventive approaches can have major public health implications. An increased dietary intake of n–3 fatty acids is one such approach. This review discusses current knowledge of n–3 fatty acids.

1 August 2015 in JACC
Verified
Journal Article
Closed access
Fabrizio RicciFabrizio Ricci
Fabrizio Ricci
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
Artur FedorowskiArtur Fedorowski
Artur Fedorowski

19 February 2002 in Circulation
Verified
Journal Article
Closed access
Giuseppina BastaGiuseppina Basta
Giuseppina Basta
GLGuido Lazzerini
Guido Lazzerini
MMmarika massaro
marika massaro
TSTommaso Simoncini
Tommaso Simoncini
PTPiero Tanganelli
Piero Tanganelli
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
Background — The products of nonenzymatic glycation and oxidation of proteins, the advanced glycation end products (AGEs), form under diverse circumstances such as aging, diabetes, and kidney failure. Recent studies suggested that AGEs may form in inflamed foci, driven by oxidation or the myeloperoxidase pathway. A principal means by which AGEs alter cellular properties is through interaction with their signal-transduction receptor RAGE. We tested the hypothesis that interaction of AGEs with RAGE on endothelial cells enhances vascular activation. Methods and Results — AGEs, RAGE, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin are expressed in an overlapping manner in human inflamed rheumatoid synovia, especially within the endothelium. In primary cultures of human saphenous vein endothelial cells, engagement of RAGE by heterogeneous AGEs or N ε(carboxymethyl)lysine–modified adducts enhanced levels of mRNA and antigen for vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin. AGEs increased adhesion of polymorphonuclear leukocytes to stimulated endothelial cells in a manner reduced on blockade of RAGE. Conclusions — AGEs, through RAGE, may prime proinflammatory mechanisms in endothelial cells, thereby amplifying proinflammatory mechanisms in atherogenesis and chronic inflammatory disorders.

8 December 2017 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
SMSanta Mundi
Santa Mundi
MMmarika massaro
marika massaro
Egeria ScodittiEgeria Scoditti
Egeria Scoditti
Maria Annunziata CarluccioMaria Annunziata Carluccio
Maria Annunziata Carluccio
VHVictor W M van Hinsbergh
Victor W M van Hinsbergh
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
Early atherosclerosis features functional and structural changes in the endothelial barrier function that affect the traffic of molecules and solutes between the vessel lumen and the vascular wall. Such changes are mechanistically related to the development of atherosclerosis. Proatherogenic stimuli and cardiovascular risk factors, such as dyslipidaemias, diabetes, obesity, and smoking, all increase endothelial permeability sharing a common signalling denominator: an imbalance in the production/disposal of reactive oxygen species (ROS), broadly termed oxidative stress. Mostly as a consequence of the activation of enzymatic systems leading to ROS overproduction, proatherogenic factors lead to a pro-inflammatory status that translates in changes in gene expression and functional rearrangements, including changes in the transendothelial transport of molecules, leading to the deposition of low-density lipoproteins (LDL) and the subsequent infiltration of circulating leucocytes in the intima. In this review, we focus on such early changes in atherogenesis and on the concept that proatherogenic stimuli and risk factors for cardiovascular disease, by altering the endothelial barrier properties, co-ordinately trigger the accumulation of LDL in the intima and ultimately plaque formation.

1 January 2013 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
SHSteen Husted
Steen Husted
LWLars Wallentin
Lars Wallentin
FAFelicita Andreotti
Felicita Andreotti
HAHarald Arnesen
Harald Arnesen
FBFedor Bachmann
Fedor Bachmann
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina
Summary: Oral anticoagulants are a mainstay of cardiovascular therapy, and for over 60 years vitamin K antagonists (VKAs) were the only available agents for long-term use. VKAs interfere with the cyclic inter-conversion of vitamin K and its 2,3 epoxide, thus inhibiting γ-carboxylation of glutamate residues at the amino-termini of vitamin K-dependent proteins, including the coagulation factors (F) II (prothrombin), VII, IX and X, as well as of the anticoagulant proteins C, S and Z. The overall effect of such interference is a dose-dependent anticoagulant effect, which has been therapeutically exploited in heart disease since the early 1950s. In this position paper, we review the mechanisms of action, pharmacological properties and side effects of VKAs, which are used in the management of cardiovascular diseases, including coronary heart disease (where their use is limited), stroke prevention in atrial fibrillation, heart valves and/or chronic heart failure. Using an evidence-based approach, we describe the results of completed clinical trials, highlight areas of uncertainty, and recommend therapeutic options for specific disorders. Although VKAs are being increasingly replaced in most patients with non-valvular atrial fibrillation by the new oral anticoagulants, which target either thrombin or FXa, the VKAs remain the agents of choice for patients with atrial fibrillation in the setting of rheumatic valvular disease and for those with mechanical heart valves.